Duke Appiah1, Pamela J Schreiner2, Richard F MacLehose2, Aaron R Folsom2. 1. From the Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis. dappiah@umn.edu. 2. From the Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis.
Abstract
OBJECTIVES: To prospectively examine the association of plasma γ' fibrinogen with the incidence of multiple cardiovascular disease (CVD) end points, independent of established CVD risk factors, total fibrinogen, and other inflammatory markers. APPROACH AND RESULTS: The Atherosclerosis Risk in Communities (ARIC) study measured γ' fibrinogen by enzyme-linked immunosorbent assay in stored plasma samples from 1993 to 1995 and related levels in 10 601 adults to incident CVD end points (coronary heart disease [n=1603], ischemic stroke [n=548], peripheral artery disease [n=599], heart failure [n=1411], and CVD mortality [n=705]) through 2012 (median follow-up, 18 years). In Cox models accounting for established CVD risk factors and total fibrinogen levels, γ' fibrinogen was associated positively with peripheral artery disease (hazard ratio [HR] per 1-SD [8.80 mg/dL] increment, 1.14 [1.04-1.24]), heart failure (HR, 1.06 [1.01-1.13]), and CVD deaths (HR, 1.12 [1.04-1.21]) but not with incident coronary heart disease (HR, 1.01 [0.96-1.07]) or ischemic stroke (HR, 0.98 [0.89-1.07]). Additional adjustment for C-reactive protein, however, eliminated the associations with peripheral artery disease and heart failure. CONCLUSIONS: These findings do not lend support to the hypothesis that γ' fibrinogen influences CVD events through its prothrombotic properties. Rather, γ' fibrinogen concentrations seem to reflect general inflammation that accompanies and may contribute to atherosclerotic CVD, instead of γ' fibrinogen being a causal risk factor.
OBJECTIVES: To prospectively examine the association of plasma γ' fibrinogen with the incidence of multiple cardiovascular disease (CVD) end points, independent of established CVD risk factors, total fibrinogen, and other inflammatory markers. APPROACH AND RESULTS: The Atherosclerosis Risk in Communities (ARIC) study measured γ' fibrinogen by enzyme-linked immunosorbent assay in stored plasma samples from 1993 to 1995 and related levels in 10 601 adults to incident CVD end points (coronary heart disease [n=1603], ischemic stroke [n=548], peripheral artery disease [n=599], heart failure [n=1411], and CVD mortality [n=705]) through 2012 (median follow-up, 18 years). In Cox models accounting for established CVD risk factors and total fibrinogen levels, γ' fibrinogen was associated positively with peripheral artery disease (hazard ratio [HR] per 1-SD [8.80 mg/dL] increment, 1.14 [1.04-1.24]), heart failure (HR, 1.06 [1.01-1.13]), and CVD deaths (HR, 1.12 [1.04-1.21]) but not with incident coronary heart disease (HR, 1.01 [0.96-1.07]) or ischemic stroke (HR, 0.98 [0.89-1.07]). Additional adjustment for C-reactive protein, however, eliminated the associations with peripheral artery disease and heart failure. CONCLUSIONS: These findings do not lend support to the hypothesis that γ' fibrinogen influences CVD events through its prothrombotic properties. Rather, γ' fibrinogen concentrations seem to reflect general inflammation that accompanies and may contribute to atherosclerotic CVD, instead of γ' fibrinogen being a causal risk factor.
Authors: Rehana S Lovely; Steven C Kazmierczak; Joseph M Massaro; Ralph B D'Agostino; Christopher J O'Donnell; David H Farrell Journal: Clin Chem Date: 2010-03-26 Impact factor: 8.327
Authors: Rehana S Lovely; Qiong Yang; Joseph M Massaro; Jing Wang; Ralph B D'Agostino; Christopher J O'Donnell; Jackilen Shannon; David H Farrell Journal: Arterioscler Thromb Vasc Biol Date: 2011-07-14 Impact factor: 8.311
Authors: Elim Y L Cheung; Hans L Vos; Marieke J H A Kruip; Heleen M den Hertog; J Wouter Jukema; Moniek P M de Maat Journal: Blood Date: 2009-11-12 Impact factor: 22.113
Authors: Evita G van den Herik; Elim Y L Cheung; Lonneke M L de Lau; Heleen M den Hertog; Frank W Leebeek; Diederik W J Dippel; Peter J Koudstaal; Moniek P M de Maat Journal: Thromb Haemost Date: 2010-12-06 Impact factor: 5.249
Authors: Rehana S Lovely; Chantelle M Rein; Tara C White; Sari A Jouihan; Lynn K Boshkov; Antony C Bakke; Owen J McCarty; David H Farrell Journal: Thromb Haemost Date: 2008-11 Impact factor: 5.249
Authors: Elim Y L Cheung; Shirley Uitte de Willige; Hans L Vos; Frank W G Leebeek; Diederik W J Dippel; Rogier M Bertina; Moniek P M de Maat Journal: Stroke Date: 2008-01-31 Impact factor: 7.914
Authors: David H Farrell; Elizabeth A Rick; Elizabeth N Dewey; Martin A Schreiber; Susan E Rowell Journal: Am J Surg Date: 2019-12-28 Impact factor: 2.565
Authors: Jillian Maners; Dipender Gill; Nathan Pankratz; Michael A Laffan; Alisa S Wolberg; Moniek P M de Maat; Symen Ligthart; Weihong Tang; Cavin K Ward-Caviness; Myriam Fornage; Stephanie Debette; Martin Dichgans; Barbara McKnight; Eric Boerwinkle; Nicholas L Smith; Alanna C Morrison; Abbas Dehghan; Paul S de Vries Journal: Blood Date: 2020-12-24 Impact factor: 22.113
Authors: Omid Azimzadeh; Christine von Toerne; Vikram Subramanian; Wolfgang Sievert; Gabriele Multhoff; Michael J Atkinson; Soile Tapio Journal: Front Public Health Date: 2021-07-02